3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Myelodysplastic Syndromes
56
Leukemia, Myeloid, Acute
53
Precursor Cell Lymphoblastic Leukemia-Lymphoma
29
Leukemia
28
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
26
Hodgkin Disease
22
Lymphoma, Non-Hodgkin
21
Multiple Myeloma
18
Leukemia, Lymphocytic, Chronic, B-Cell
17
Myeloproliferative Disorders
15
Lymphoma
12
Leukemia, Myelomonocytic, Chronic
11
Leukemia, Biphenotypic, Acute
10
Anemia, Refractory, with Excess of Blasts
10
Blast Crisis
9
Neoplasms, Plasma Cell
8
Lymphoma, B-Cell, Marginal Zone
8
Burkitt Lymphoma
8
Primary Myelofibrosis
7
Lymphoma, Mantle-Cell
7
Lymphoma, Follicular
7
Congenital Abnormalities
7
Leukemia, Myelomonocytic, Juvenile
6
Leukemia, Myeloid, Chronic-Phase
6
Graft vs Host Disease
6
Lymphoma, Large-Cell, Immunoblastic
5
Lymphoma, Large B-Cell, Diffuse
5
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
5
Leukemia, Myeloid, Accelerated Phase
5
Hematologic Neoplasms
5
Interventions
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Congenital Bone Marrow Failure Syndromes
×
Granulocyte Colony-Stimulating Factor
×
Myeloid
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled